Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Masood, Muaaz, Coles, Michael, Sifuentes, Humberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263270/
https://www.ncbi.nlm.nih.gov/pubmed/34306771
http://dx.doi.org/10.1155/2021/2242178
_version_ 1783719356035760128
author Masood, Muaaz
Coles, Michael
Sifuentes, Humberto
author_facet Masood, Muaaz
Coles, Michael
Sifuentes, Humberto
author_sort Masood, Muaaz
collection PubMed
description Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.
format Online
Article
Text
id pubmed-8263270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82632702021-07-22 Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab Masood, Muaaz Coles, Michael Sifuentes, Humberto Case Rep Gastrointest Med Case Report Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis. Hindawi 2021-06-29 /pmc/articles/PMC8263270/ /pubmed/34306771 http://dx.doi.org/10.1155/2021/2242178 Text en Copyright © 2021 Muaaz Masood et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Masood, Muaaz
Coles, Michael
Sifuentes, Humberto
Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title_full Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title_fullStr Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title_full_unstemmed Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title_short Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
title_sort management of refractory gastrointestinal bleeding in hereditary hemorrhagic telangiectasia with bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263270/
https://www.ncbi.nlm.nih.gov/pubmed/34306771
http://dx.doi.org/10.1155/2021/2242178
work_keys_str_mv AT masoodmuaaz managementofrefractorygastrointestinalbleedinginhereditaryhemorrhagictelangiectasiawithbevacizumab
AT colesmichael managementofrefractorygastrointestinalbleedinginhereditaryhemorrhagictelangiectasiawithbevacizumab
AT sifuenteshumberto managementofrefractorygastrointestinalbleedinginhereditaryhemorrhagictelangiectasiawithbevacizumab

Ejemplares similares